###begin article-title 0
Serum concentration of C-reactive protein is not a good marker of bronchial hyperresponsiveness
###end article-title 0
###begin title 1
Introduction:
###end title 1
###begin p 2
Asthmatic inflammation is responsible for vital features of the disease, including bronchial hyperresponsiveness (BHR). At present we do not have precise markers for monitoring asthmatic inflammation. C-reactive protein (CRP), a marker of systemic inflammation, seemed to be a factor which could also reflect the level of asthmatic inflammation expressed by BHR. Therefore the relationship between CRP concentration and BHR was evaluated.
###end p 2
###begin title 3
Materials and Methods:
###end title 3
###begin p 4
###xml 20 28 <span type="species:ncbi:9606">patients</span>
One hundred and two patients entered the study. A skin prick test with a broad spectrum of common aeroallergens as well as baseline spirometry and a histamine bronchoprovocation test were performed in each subject. Blood samples for high-sensitivity CRP (hsCRP) measurement were taken before the bronchial challenge tests.
###end p 4
###begin title 5
Results:
###end title 5
###begin p 6
###xml 207 215 <span type="species:ncbi:9606">patients</span>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
Serum hsCRP concentrations ranged from 0.20 to 14.5 mg/l (median: 1.2 mg/l, 25-75% quartiles: 0.6-2.4). Positive skin prick tests were found in 26 subjects. Bronchial hyperresponsiveness was confirmed in 42 patients (first subgroup), while 60 subjects did not demonstrate BHR (second subgroup). Among the patients with BHR, asthma was diagnosed in 33 cases and Corrao syndrome in 9. In both subgroups, serum hsCRP concentrations had similar levels (median: 1.4 mg/l, 25-75% quartiles: 0.8-2.4 and median: 0.9 mg/l, 25-75% quartiles: 0.5-2.8, respectively; p=0.297). There was no statistically significant correlation (r= -0.163, p=0.302) between serum hsCRP concentration and the level of BHR expressed as the 20% provocative concentration for histamine. In addition, hsCRP serum concentration, after adjustment for age, atopy, body mass index, and gender, was not a significant predictor of positive histamine bronchoprovocation test results (p=0.22, OR=0.86, 95% CI).
###end p 6
###begin title 7
Conclusions:
###end title 7
###begin p 8
Serum hsCRP concentration is not a good marker of BHR, which is mainly dependent on asthmatic inflammation and is measured during bronchial challenge with histamine. This finding is important for interpreting and discussing results obtained from epidemiological and population-based studies on relationships between either CRP concentration and BHR or local and systemic inflammation.
###end p 8
###begin title 9
Keywords:
###end title 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 293 295 293 295 <sub xmlns:xlink="http://www.w3.org/1999/xlink">20</sub>
###xml 422 424 422 424 <sub xmlns:xlink="http://www.w3.org/1999/xlink">20</sub>
###xml 899 900 899 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 902 904 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 931 932 931 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 934 936 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 964 966 964 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 968 970 968 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 972 974 972 974 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1261 1262 1261 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 636 643 <span type="species:ncbi:9606">patient</span>
Bronchial hyperresponsiveness (BHR) is a crucial attribute of asthma. It is due to chronic asthmatic inflammation and may reflect the level of the inflammatory process [16]. Direct airway challenge with histamine or metacholine discloses BHR, expressed as the 20% provocative concentration (PC20) value, and is also used for assessing the potential anti-inflammatory effects of treatment with new agents. However, using PC20 for histamine which reflects the BHR level, though priceless in the diagnosis of asthma, is not valuable in monitoring asthmatic inflammation. Airway challenge with histamine is accompanied by discomfort to the patient and sometimes produces life-threatening situations; moreover, it is expensive and time consuming for medical staff. Other means of assessing airway inflammation in asthma, such as the evaluation of many markers in induced sputum (cytokines, eosinophils) [6, 22], bronchoalveolar lavage [5, 10], or exhaled air (NO, CO) [13, 16, 18], share the same inconveniences as the determination of BHR. On the other hand, convincing data show that bronchial asthma treatment developed on the basis of inflammatory premises is more effective than treatment which considers the classical British Thoracic Society recommendations [6].
###end p 11
###begin p 12
###xml 171 172 171 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 177 179 177 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 598 599 598 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 1076 1078 1076 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 1163 1165 1163 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 1273 1275 1273 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 1302 1304 1302 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 1319 1320 1319 1320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 1344 1346 1344 1346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 1475 1476 1475 1476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 1506 1508 1506 1508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 530 538 <span type="species:ncbi:9606">patients</span>
###xml 1066 1074 <span type="species:ncbi:9606">patients</span>
Recent publications suggest that C-reactive protein (CRP) could be taken into consideration as a simple, cheap, and reliable marker for monitoring asthmatic inflammation [8, 9, 17]. If this hypothesis was true, there should be a noticeable interrelationship between CRP and some BHR indices such as direct airway challenges results. Theoretically, CRP should not exist in a healthy organism, but even minimal exciting factors including age, body mass index (BMI), gender, smoking and variability of blood pressure in normotensive patients may either trigger or bias trace amount of CRP production [1]. Therefore, a CRP concentration of <5 mg/l is accepted as the normal value. The normal median concentration of CRP is 0.8 mg/l, with 90% of apparently healthy individuals having a value less than 3 mg/l and 99% less than 12 mg/l. It is produced by the liver at a higher concentration when the organism is challenged by a significant inflammatory stimulus, such as endotoxins from the membranes of Gram-negative bacteria inhaled into the bronchial tree of asthmatic patients [14]. It is well known that CRP increases during infection and autoimmune disturbances [20]. Much attention has been focused lately on CRP in cardiovascular diseases, such as chronic heart failure [26], ischemic heart disease [12], arrhythmia [2], and atherosclerosis [27]. Especially interesting are publications pointing to CRP as a marker which may have prognostic value in ischemic heart attack [3] and irregularity of rhythm [11].
###end p 12
###begin p 13
###xml 97 98 97 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 102 103 102 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 163 164 163 164 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 168 169 168 169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 513 514 513 514 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
The main question concerns the relationships between local asthmatic inflammation, mediated by Th2 CD4+ lymphocytes, and systemic inflammation, which depends on Th1 CD4+ lymphocytes. At present, very little is known about this, but it must be realized that such relationships, even complex ones, exist and one segment of the immune response influences another, also resulting in CRP production [25]. Interesting experimental data suggest that CRP may inhibit local inflammatory effects and also protect against Th2-mediated reactions [21]. Being aware of these relationships, as well as the circumstances, we developed this study using a purely clinical model to determine whether CRP may be a marker of asthmatic inflammation, expressed by BHR, and thus be useful in monitoring this process and predicting asthma severity and exacerbation.
###end p 13
###begin title 14
Materials and Methods
###end title 14
###begin title 15
###xml 6 18 <span type="species:ncbi:9606">participants</span>
Study participants
###end title 15
###begin p 16
###xml 1417 1418 1415 1416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1529 1536 1527 1534 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table 1</label>
###xml 1536 1660 1534 1658 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="17">Demographic data, spirometric values, and hsCRP serum concentrations in the entire sample and subgroups with and without BHR</p>
###xml 1536 1660 1534 1658 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="17">Demographic data, spirometric values, and hsCRP serum concentrations in the entire sample and subgroups with and without BHR</p></caption>
###xml 1660 1660 1658 1658 <th xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1660 1681 1658 1675 <th xmlns:xlink="http://www.w3.org/1999/xlink">Age (years) &#967;&#175;&#177;SD</th>
###xml 1681 1694 1675 1688 <th xmlns:xlink="http://www.w3.org/1999/xlink">Male/female n</th>
###xml 1694 1715 1688 1705 <th xmlns:xlink="http://www.w3.org/1999/xlink">Weight (kg) &#967;&#175;&#177;SD</th>
###xml 1715 1736 1705 1722 <th xmlns:xlink="http://www.w3.org/1999/xlink">Height (cm) &#967;&#175;&#177;SD</th>
###xml 1736 1753 1722 1735 <th xmlns:xlink="http://www.w3.org/1999/xlink">FVC (%) &#967;&#175;&#177;SD</th>
###xml 1753 1771 1735 1749 <th xmlns:xlink="http://www.w3.org/1999/xlink">FEV1 (%) &#967;&#175;&#177;SD</th>
###xml 1771 1784 1749 1758 <th xmlns:xlink="http://www.w3.org/1999/xlink">BMI &#967;&#175;&#177;SD</th>
###xml 1784 1804 1758 1778 <th xmlns:xlink="http://www.w3.org/1999/xlink">CRP (mg/l) Me 25&#8211;75%</th>
###xml 1806 1808 1780 1782 <sub xmlns:xlink="http://www.w3.org/1999/xlink">20</sub>
###xml 1804 1826 1778 1796 <th xmlns:xlink="http://www.w3.org/1999/xlink">PC<sub>20</sub> (mg/ml) &#967;&#175;&#177;SD</th>
###xml 1660 1826 1658 1796 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th/><th>Age (years) &#967;&#175;&#177;SD</th><th>Male/female n</th><th>Weight (kg) &#967;&#175;&#177;SD</th><th>Height (cm) &#967;&#175;&#177;SD</th><th>FVC (%) &#967;&#175;&#177;SD</th><th>FEV1 (%) &#967;&#175;&#177;SD</th><th>BMI &#967;&#175;&#177;SD</th><th>CRP (mg/l) Me 25&#8211;75%</th><th>PC<sub>20</sub> (mg/ml) &#967;&#175;&#177;SD</th></tr>
###xml 1660 1826 1658 1796 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th/><th>Age (years) &#967;&#175;&#177;SD</th><th>Male/female n</th><th>Weight (kg) &#967;&#175;&#177;SD</th><th>Height (cm) &#967;&#175;&#177;SD</th><th>FVC (%) &#967;&#175;&#177;SD</th><th>FEV1 (%) &#967;&#175;&#177;SD</th><th>BMI &#967;&#175;&#177;SD</th><th>CRP (mg/l) Me 25&#8211;75%</th><th>PC<sub>20</sub> (mg/ml) &#967;&#175;&#177;SD</th></tr></thead>
###xml 1826 1894 1796 1864 <td xmlns:xlink="http://www.w3.org/1999/xlink">Demographic data, spirometric, and CRP values: entire sample (n=102)</td>
###xml 1894 1905 1864 1873 <td xmlns:xlink="http://www.w3.org/1999/xlink">38.9&#177;14.8</td>
###xml 1905 1910 1873 1878 <td xmlns:xlink="http://www.w3.org/1999/xlink">29/73</td>
###xml 1910 1921 1878 1887 <td xmlns:xlink="http://www.w3.org/1999/xlink">70.7&#177;13.6</td>
###xml 1921 1933 1887 1897 <td xmlns:xlink="http://www.w3.org/1999/xlink">166.6&#177;10.2</td>
###xml 1933 1945 1897 1907 <td xmlns:xlink="http://www.w3.org/1999/xlink">102.0&#177;13.1</td>
###xml 1945 1957 1907 1917 <td xmlns:xlink="http://www.w3.org/1999/xlink">102.5&#177;14.8</td>
###xml 1957 1975 1917 1933 <td xmlns:xlink="http://www.w3.org/1999/xlink">25.4&#177;4.4 0.6&#8722;2.4</td>
###xml 1975 1978 1933 1936 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.2</td>
###xml 1978 1987 1936 1943 <td xmlns:xlink="http://www.w3.org/1999/xlink">7.1&#177;6.7</td>
###xml 1826 1987 1796 1943 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Demographic data, spirometric, and CRP values: entire sample (n=102)</td><td>38.9&#177;14.8</td><td>29/73</td><td>70.7&#177;13.6</td><td>166.6&#177;10.2</td><td>102.0&#177;13.1</td><td>102.5&#177;14.8</td><td>25.4&#177;4.4 0.6&#8722;2.4</td><td>1.2</td><td>7.1&#177;6.7</td></tr>
###xml 1987 2014 1943 1970 <td xmlns:xlink="http://www.w3.org/1999/xlink">Positive test result (n=42)</td>
###xml 2014 2025 1970 1979 <td xmlns:xlink="http://www.w3.org/1999/xlink">44.8&#177;15.6</td>
###xml 2025 2029 1979 1983 <td xmlns:xlink="http://www.w3.org/1999/xlink">8/34</td>
###xml 2029 2040 1983 1992 <td xmlns:xlink="http://www.w3.org/1999/xlink">70.2&#177;11.0</td>
###xml 2040 2051 1992 2001 <td xmlns:xlink="http://www.w3.org/1999/xlink">164.2&#177;7.9</td>
###xml 2051 2063 2001 2011 <td xmlns:xlink="http://www.w3.org/1999/xlink">101.0&#177;13.3</td>
###xml 2063 2075 2011 2021 <td xmlns:xlink="http://www.w3.org/1999/xlink">101.3&#177;14.6</td>
###xml 2075 2085 2021 2029 <td xmlns:xlink="http://www.w3.org/1999/xlink">26.1&#177;4.5</td>
###xml 2085 2096 2029 2040 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.4 0.8&#8722;2.4</td>
###xml 2096 2105 2040 2047 <td xmlns:xlink="http://www.w3.org/1999/xlink">7.1&#177;6.7</td>
###xml 1987 2105 1943 2047 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Positive test result (n=42)</td><td>44.8&#177;15.6</td><td>8/34</td><td>70.2&#177;11.0</td><td>164.2&#177;7.9</td><td>101.0&#177;13.3</td><td>101.3&#177;14.6</td><td>26.1&#177;4.5</td><td>1.4 0.8&#8722;2.4</td><td>7.1&#177;6.7</td></tr>
###xml 2105 2132 2047 2074 <td xmlns:xlink="http://www.w3.org/1999/xlink">Negative test result (n=60)</td>
###xml 2132 2143 2074 2083 <td xmlns:xlink="http://www.w3.org/1999/xlink">34.8&#177;12.8</td>
###xml 2143 2148 2083 2088 <td xmlns:xlink="http://www.w3.org/1999/xlink">21/39</td>
###xml 2148 2159 2088 2097 <td xmlns:xlink="http://www.w3.org/1999/xlink">71.1&#177;15.3</td>
###xml 2159 2171 2097 2107 <td xmlns:xlink="http://www.w3.org/1999/xlink">168.3&#177;11.2</td>
###xml 2171 2183 2107 2117 <td xmlns:xlink="http://www.w3.org/1999/xlink">102.7&#177;13.1</td>
###xml 2183 2195 2117 2127 <td xmlns:xlink="http://www.w3.org/1999/xlink">103.3&#177;15.0</td>
###xml 2195 2205 2127 2135 <td xmlns:xlink="http://www.w3.org/1999/xlink">24.9&#177;4.3</td>
###xml 2205 2216 2135 2146 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.9 0.5&#8722;2.8</td>
###xml 2216 2216 2146 2146 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2105 2216 2047 2146 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Negative test result (n=60)</td><td>34.8&#177;12.8</td><td>21/39</td><td>71.1&#177;15.3</td><td>168.3&#177;11.2</td><td>102.7&#177;13.1</td><td>103.3&#177;15.0</td><td>24.9&#177;4.3</td><td>0.9 0.5&#8722;2.8</td><td/></tr>
###xml 2216 2216 2146 2146 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2216 2225 2146 2155 <td xmlns:xlink="http://www.w3.org/1999/xlink">p=0.0006*</td>
###xml 2225 2234 2155 2164 <td xmlns:xlink="http://www.w3.org/1999/xlink">p=0.125**</td>
###xml 2234 2242 2164 2172 <td xmlns:xlink="http://www.w3.org/1999/xlink">p=0.769*</td>
###xml 2242 2250 2172 2180 <td xmlns:xlink="http://www.w3.org/1999/xlink">p=0.047*</td>
###xml 2250 2258 2180 2188 <td xmlns:xlink="http://www.w3.org/1999/xlink">p=0.526*</td>
###xml 2258 2266 2188 2196 <td xmlns:xlink="http://www.w3.org/1999/xlink">p=0.503*</td>
###xml 2266 2274 2196 2204 <td xmlns:xlink="http://www.w3.org/1999/xlink">p=0.184*</td>
###xml 2274 2284 2204 2214 <td xmlns:xlink="http://www.w3.org/1999/xlink">p=0.297***</td>
###xml 2284 2284 2214 2214 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 2216 2284 2146 2214 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>p=0.0006*</td><td>p=0.125**</td><td>p=0.769*</td><td>p=0.047*</td><td>p=0.526*</td><td>p=0.503*</td><td>p=0.184*</td><td>p=0.297***</td><td/></tr>
###xml 1826 2284 1796 2214 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Demographic data, spirometric, and CRP values: entire sample (n=102)</td><td>38.9&#177;14.8</td><td>29/73</td><td>70.7&#177;13.6</td><td>166.6&#177;10.2</td><td>102.0&#177;13.1</td><td>102.5&#177;14.8</td><td>25.4&#177;4.4 0.6&#8722;2.4</td><td>1.2</td><td>7.1&#177;6.7</td></tr><tr><td>Positive test result (n=42)</td><td>44.8&#177;15.6</td><td>8/34</td><td>70.2&#177;11.0</td><td>164.2&#177;7.9</td><td>101.0&#177;13.3</td><td>101.3&#177;14.6</td><td>26.1&#177;4.5</td><td>1.4 0.8&#8722;2.4</td><td>7.1&#177;6.7</td></tr><tr><td>Negative test result (n=60)</td><td>34.8&#177;12.8</td><td>21/39</td><td>71.1&#177;15.3</td><td>168.3&#177;11.2</td><td>102.7&#177;13.1</td><td>103.3&#177;15.0</td><td>24.9&#177;4.3</td><td>0.9 0.5&#8722;2.8</td><td/></tr><tr><td/><td>p=0.0006*</td><td>p=0.125**</td><td>p=0.769*</td><td>p=0.047*</td><td>p=0.526*</td><td>p=0.503*</td><td>p=0.184*</td><td>p=0.297***</td><td/></tr></tbody>
###xml 1660 2284 1658 2214 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th/><th>Age (years) &#967;&#175;&#177;SD</th><th>Male/female n</th><th>Weight (kg) &#967;&#175;&#177;SD</th><th>Height (cm) &#967;&#175;&#177;SD</th><th>FVC (%) &#967;&#175;&#177;SD</th><th>FEV1 (%) &#967;&#175;&#177;SD</th><th>BMI &#967;&#175;&#177;SD</th><th>CRP (mg/l) Me 25&#8211;75%</th><th>PC<sub>20</sub> (mg/ml) &#967;&#175;&#177;SD</th></tr></thead><tbody><tr><td>Demographic data, spirometric, and CRP values: entire sample (n=102)</td><td>38.9&#177;14.8</td><td>29/73</td><td>70.7&#177;13.6</td><td>166.6&#177;10.2</td><td>102.0&#177;13.1</td><td>102.5&#177;14.8</td><td>25.4&#177;4.4 0.6&#8722;2.4</td><td>1.2</td><td>7.1&#177;6.7</td></tr><tr><td>Positive test result (n=42)</td><td>44.8&#177;15.6</td><td>8/34</td><td>70.2&#177;11.0</td><td>164.2&#177;7.9</td><td>101.0&#177;13.3</td><td>101.3&#177;14.6</td><td>26.1&#177;4.5</td><td>1.4 0.8&#8722;2.4</td><td>7.1&#177;6.7</td></tr><tr><td>Negative test result (n=60)</td><td>34.8&#177;12.8</td><td>21/39</td><td>71.1&#177;15.3</td><td>168.3&#177;11.2</td><td>102.7&#177;13.1</td><td>103.3&#177;15.0</td><td>24.9&#177;4.3</td><td>0.9 0.5&#8722;2.8</td><td/></tr><tr><td/><td>p=0.0006*</td><td>p=0.125**</td><td>p=0.769*</td><td>p=0.047*</td><td>p=0.526*</td><td>p=0.503*</td><td>p=0.184*</td><td>p=0.297***</td><td/></tr></tbody></table>
###xml 2310 2311 2240 2241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 2284 2392 2214 2320 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="18">* Calculated by Student's <italic>t</italic>-test, ** calculated by &#967;&#175;-squared-test, *** calculated by Mann-Withney U-test.</p>
###xml 2392 2465 2320 2391 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="19">&#967;&#175;-Arithmetic mean, SD-standard deviation, Me-median, 25&#8211;75% quartiles.</p>
###xml 2284 2465 2214 2391 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="18">* Calculated by Student's <italic>t</italic>-test, ** calculated by &#967;&#175;-squared-test, *** calculated by Mann-Withney U-test.</p><p textid="19">&#967;&#175;-Arithmetic mean, SD-standard deviation, Me-median, 25&#8211;75% quartiles.</p></table-wrap-foot>
###xml 1529 2465 1527 2391 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table 1</label><caption><p textid="17">Demographic data, spirometric values, and hsCRP serum concentrations in the entire sample and subgroups with and without BHR</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Age (years) &#967;&#175;&#177;SD</th><th>Male/female n</th><th>Weight (kg) &#967;&#175;&#177;SD</th><th>Height (cm) &#967;&#175;&#177;SD</th><th>FVC (%) &#967;&#175;&#177;SD</th><th>FEV1 (%) &#967;&#175;&#177;SD</th><th>BMI &#967;&#175;&#177;SD</th><th>CRP (mg/l) Me 25&#8211;75%</th><th>PC<sub>20</sub> (mg/ml) &#967;&#175;&#177;SD</th></tr></thead><tbody><tr><td>Demographic data, spirometric, and CRP values: entire sample (n=102)</td><td>38.9&#177;14.8</td><td>29/73</td><td>70.7&#177;13.6</td><td>166.6&#177;10.2</td><td>102.0&#177;13.1</td><td>102.5&#177;14.8</td><td>25.4&#177;4.4 0.6&#8722;2.4</td><td>1.2</td><td>7.1&#177;6.7</td></tr><tr><td>Positive test result (n=42)</td><td>44.8&#177;15.6</td><td>8/34</td><td>70.2&#177;11.0</td><td>164.2&#177;7.9</td><td>101.0&#177;13.3</td><td>101.3&#177;14.6</td><td>26.1&#177;4.5</td><td>1.4 0.8&#8722;2.4</td><td>7.1&#177;6.7</td></tr><tr><td>Negative test result (n=60)</td><td>34.8&#177;12.8</td><td>21/39</td><td>71.1&#177;15.3</td><td>168.3&#177;11.2</td><td>102.7&#177;13.1</td><td>103.3&#177;15.0</td><td>24.9&#177;4.3</td><td>0.9 0.5&#8722;2.8</td><td/></tr><tr><td/><td>p=0.0006*</td><td>p=0.125**</td><td>p=0.769*</td><td>p=0.047*</td><td>p=0.526*</td><td>p=0.503*</td><td>p=0.184*</td><td>p=0.297***</td><td/></tr></tbody></table><table-wrap-foot><p textid="18">* Calculated by Student's <italic>t</italic>-test, ** calculated by &#967;&#175;-squared-test, *** calculated by Mann-Withney U-test.</p><p textid="19">&#967;&#175;-Arithmetic mean, SD-standard deviation, Me-median, 25&#8211;75% quartiles.</p></table-wrap-foot></table-wrap>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
The study group consisted of 102 patients, 29 male and 73 female aged 16-74 years (average: 38.9+/-14.8 years), who were admitted to our department with the suspicion of asthma or Corrao syndrome. All subjects enrolled in the study were free of any medication for at least two weeks before the trial and were steroid naive and nonsmokers. Precise clinical evaluation allowed exclusion of chronic inflammatory and systemic diseases, particularly those of pulmonary, cardiovascular, or autoimmune origin. Anamnesis and detailed physical examination did not reveal any abnormalities, and particularly blood pressure and heart rate were within the normal ranges. X-ray images of the nasal sinuses and chest as well as computed tomography, performed in some cases, did not display changes in the upper and lower airways and lungs. Any uncertainty in a diagnosis was explained by means of bronchoscopy. Electrocardiography tracings and echocardiography did not demonstrate heart rhythm disturbances, heart failure, or pulmonary hypertension. There were no disturbances in erythrocyte sedimentation rate, blood cell count, the concentrations of glucose, uric acid, or blood lipids, and the partial pressure of blood gases. In particular cases, serologic evaluation was undertaken to evaluate rheumatoid factor and anti-DNA antibodies, which were negative. Detailed demographic data and spirometric values are shown in Table 1. The study was approved by the local ethics committee (Wroclaw Medical University, decision No. KB-396/2005). Table 1Demographic data, spirometric values, and hsCRP serum concentrations in the entire sample and subgroups with and without BHRAge (years) chi +/-SDMale/female nWeight (kg) chi +/-SDHeight (cm) chi +/-SDFVC (%) chi +/-SDFEV1 (%) chi +/-SDBMI chi +/-SDCRP (mg/l) Me 25-75%PC20 (mg/ml) chi +/-SDDemographic data, spirometric, and CRP values: entire sample (n=102)38.9+/-14.829/7370.7+/-13.6166.6+/-10.2102.0+/-13.1102.5+/-14.825.4+/-4.4 0.6-2.41.27.1+/-6.7Positive test result (n=42)44.8+/-15.68/3470.2+/-11.0164.2+/-7.9101.0+/-13.3101.3+/-14.626.1+/-4.51.4 0.8-2.47.1+/-6.7Negative test result (n=60)34.8+/-12.821/3971.1+/-15.3168.3+/-11.2102.7+/-13.1103.3+/-15.024.9+/-4.30.9 0.5-2.8p=0.0006*p=0.125**p=0.769*p=0.047*p=0.526*p=0.503*p=0.184*p=0.297**** Calculated by Student's t-test, ** calculated by chi -squared-test, *** calculated by Mann-Withney U-test.chi -Arithmetic mean, SD-standard deviation, Me-median, 25-75% quartiles.
###end p 16
###begin p 17
Demographic data, spirometric values, and hsCRP serum concentrations in the entire sample and subgroups with and without BHR
###end p 17
###begin p 18
###xml 26 27 26 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
* Calculated by Student's t-test, ** calculated by chi -squared-test, *** calculated by Mann-Withney U-test.
###end p 18
###begin p 19
chi -Arithmetic mean, SD-standard deviation, Me-median, 25-75% quartiles.
###end p 19
###begin title 20
Study design
###end title 20
###begin p 21
###xml 686 688 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 892 893 892 893 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 979 980 979 980 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 1043 1045 1043 1045 <sub xmlns:xlink="http://www.w3.org/1999/xlink">20</sub>
In each subject a skin prick test with a broad spectrum of common aeroallergens as well as baseline spirometry and a histamine bronchoprovocation test were performed. Blood samples for high-sensitivity CRP (hsCRP) measurement were taken from the subjects before the challenge test with histamine. For measurements of pulmonary functions, an Alfa spirometer (Vitalograf) was used. Each spirometric parameter was recorded in triplicate and the best value of the lung function test was taken for further analysis. ACCS criteria were used for estimating predicted values. BHR was determined by the histamine bronchoprovocation test according to the European Respiratory Society guidelines [19]. The tidal breathing method was used. Histamine was administered through a de Vilbis nebulizer in progressive concentrations of 0.125, 0.250, 0.5, 1, 2, 4, 8, and 16 mg/ml. The test was stopped when FEV1 had fallen by 20% or more. A positive histamine test was defined as a decrease in FEV1 of at least 20%, and then the results were expressed as the PC20. Serum hsCRP concentrations were determined by an immunoturbidimetric assay with amplification of latex molecules on an Integra 400 analyzer (Roche).
###end p 21
###begin title 22
Statistical analysis
###end title 22
###begin p 23
###xml 144 145 144 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 274 276 272 274 <sub xmlns:xlink="http://www.w3.org/1999/xlink">20</sub>
Data were statistically analyzed with Statistica software version 6.0 (SN:AXXP412B401322AR14). To compare factors between groups, the Student's t-test, the Mann-Whitney test, and the chi-squared test were used. The interrelationship between serum hsCRP concentrations and PC20 values was assessed by Spearman's rank correlation coefficient; p values <0.05 were considered significant.
###end p 23
###begin title 24
Results
###end title 24
###begin p 25
###xml 129 130 129 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
Serum CRP concentrations in the entire sample ranged from 0.20 to 14.5 mg/l, (median: 1.2 mg/l, 25-75% quartiles: 0.6-2.4; Table 1). Positive skin-prick tests with allergen expressing one of the features of atopy were found in 26 subjects.
###end p 25
###begin p 26
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 14 26 <span type="species:ncbi:9606">participants</span>
###xml 110 118 <span type="species:ncbi:9606">patients</span>
###xml 178 186 <span type="species:ncbi:9606">patients</span>
###xml 297 309 <span type="species:ncbi:9606">participants</span>
###xml 461 469 <span type="species:ncbi:9606">patients</span>
Among the 102 participants, 42 had positive histamine bronchoprovocation test results (first subgroup) and 60 patients (second subgroup) did not present BHR (Table 1). Among the patients with BHR, asthma was diagnosed in 33 cases and its variant, characterized by coughing (Corrao syndrome), in 9 participants of this subgroup. There were no significant differences between the two subgroups in both baseline spirometric parameters and gender distribution. The patients with BHR were significantly older than those with negative bronchoprovocation results (44.8+/-15.6 and 34.8+/-12.8 years, respectively; p=0.0006).
###end p 26
###begin p 27
###xml 176 177 176 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 325 327 325 327 <sub xmlns:xlink="http://www.w3.org/1999/xlink">20</sub>
###xml 340 341 340 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
In both subgroups, serum CRP concentrations were on a similar level (median: 1.4 mg/l, 25-75% quartiles: 0.8-2.4 and median: 0.9 mg/l, 25-75% quartiles: 0.5-2.8; p=0.297; Fig. 1). There was no statistically significant correlation (r= -0.163, p=0.302) between serum CRP concentration and the level of BHR, expressed as the PC20 value (Fig. 2).
###end p 27
###begin p 28
###xml 27 35 <span type="species:ncbi:9606">patients</span>
CRP serum concentration in patients with negative (n=60) and positive (n=42) bronchoprovocation test results.
###end p 28
###begin p 29
###xml 76 78 76 78 <sub xmlns:xlink="http://www.w3.org/1999/xlink">20</sub>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Spearman's rank correlation between CRP serum concentration and histamine PC20 value in patients with positive bronchoprovocation test result (n=42).
###end p 29
###begin p 30
Logistic regression analysis showed that hsCRP serum concentration after adjustment for age, atopy, BMI, and gender cannot be considered a significant predictor of positive histamine bronchoprovocation test results (p=0.22, OR=0.86; 95% CI).
###end p 30
###begin title 31
Discussion
###end title 31
###begin p 32
###xml 753 755 753 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 787 788 787 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 790 791 790 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
The test data of this study definitely indicate that the serum concentration of hsCRP is not associated with asthmatic inflammation expressed by BHR and cannot be taken into consideration as a marker of the local inflammatory process in either atopic or non-atopic asthma. Multivariate analyses showed that this result was also independent of potential confounding factors such as age, BMI, and gender. The validity of these results are based on a purely clinical experiment and, to our knowledge, this is the first such attempt to evaluate the usefulness of measuring CRP concentration in monitoring asthmatic inflammation. The importance of our test data increases in light of a few very interesting publications, mainly of an epidemiological nature [17] and population-based studies [8, 9], which could suggest the possibility that serum CRP concentration may reflect the level of bronchial inflammation in asthma, so it could be a simple, cheap, and easy to perform test for a clinical evaluation of the disease.
###end p 32
###begin p 33
###xml 83 84 83 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 351 352 351 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 359 360 359 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 441 442 441 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1081 1082 1081 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 181 193 <span type="species:ncbi:9606">participants</span>
###xml 314 322 <span type="species:ncbi:9606">patients</span>
###xml 729 741 <span type="species:ncbi:9606">participants</span>
Among these studies is an elegant work on a population-based study by Kony et al. [9] which revealed an association between a higher frequency of BHR and higher CRP levels in study participants which could reflect local inflammation within the bronchi. In our study, hsCRP concentration in serum did not differ in patients with and without BHR (Table 1, Fig. 1). In addition, no significant correlation was found between hsCRP and BHR (Fig. 2). All these data, seemingly contradictory, may arise from a fascinating and unknown link between local and systemic inflammation in asthma, which was also emphasized by the authors of that article. The methodology used in our study excluded events of systemic inflammation in the study participants; thus we can conclude that increasing CRP concentration does not depend on asthmatic inflammation in this link. This does not mean that sensitive systemic inflammation markers other than CRP, such as serum amyloid-A and plasma fibrinogen, could be significantly associated with asthma prevalence, as shown in a study by Jousilahti et al. [8]. However, the authors demonstrated these results in a population-based study, which is a correct pattern to show relationships between systemic inflammation markers and asthma prevalence, but it does not seem to be a good model to display linkage between asthmatic and systemic inflammation.
###end p 33
###begin p 34
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 571 572 571 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 934 936 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 974 975 974 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 977 979 977 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 981 983 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 1267 1269 1267 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1308 1309 1308 1309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 1329 1331 1329 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 1352 1353 1352 1353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 1374 1376 1374 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 156 164 <span type="species:ncbi:9606">patients</span>
Other interesting data were developed as a multicenter epidemiological study by Olafsdottir et al. [17], who revealed that hsCRP concentration increases in patients with non-allergic asthma, but not in allergic asthma. The study demonstrated, however, no significant relationships between CRP, atopy, and BHR, which is as yet an indispensable feature of non-allergic asthma as well. The lack of association between CRP and BHR is in accordance with our observation; however, we did not show any significant difference when comparing atopic and non-atopic subjects (Table 1). An epidemiological study can show many valuable relationships concerning hsCRP concentration and respiratory symptoms, non-allergic asthma, and atopy, but under these circumstances, that many clinical and inflammatory factors may change the natural history of asthma. Besides BMI, smoking, age, and gender, these relationships may arise from atherosclerosis [27], many cardiovascular abnormalities [2, 12, 26], or hidden inflammatory processes which may coexist with asthma in a population-based study. Non-allergic asthma, which has the same immune pathological basis as the allergic type of the disease, substantially differs from allergic asthma at the origin of the inflammatory process [15], which probably depends on bacteria [7], viral infection [24], unknown allergen [4], or auto-allergen [23]. Systemic inflammation could thus be a reason for the CRP concentration increase in non-allergic asthma.
###end p 34
###begin p 35
###xml 28 30 28 30 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 356 357 356 357 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 755 763 <span type="species:ncbi:9606">patients</span>
The study by Szalai et al. [21] was of special interest to us as it suggested that an increase in CRP concentration may accompany the acute phase of allergic inflammation. This phenomenon may occur as a secondary reaction connected with a CRP ability to stimulate the expression of anti-inflammatory cytokine-10, which down-regulates the activity of the Th2 lymphocyte population. This observation may be an inspiration to develop a study on the significance of CRP concentration as a marker of allergic asthma exacerbation. Our study results clearly showed that hsCRP serum concentration in asthma did not correlate with BHR which, in turn, indirectly suggests its poor relationship with asthmatic inflammation. It should also be underlined that all our patients represented a subpopulation of newly diagnosed asthma without any significant concomitant diseases. Therefore we speculate that the increase in CRP concentration reported among a proportion of asthmatics in epidemiological and population-based studies might result from other conditions coexisting with chronic asthma.
###end p 35
###begin title 36
References
###end title 36
###begin article-title 37
Relation of C-reactive protein and tumor necrosis factor-alpha to ambulatory blood pressure variability in healthy adults
###end article-title 37
###begin article-title 38
Frequency of elevation of C-reactive protein in atrial fibrillation
###end article-title 38
###begin article-title 39
###xml 71 79 <span type="species:ncbi:9606">patients</span>
C-reactive protein and the stress tests for the risk stratification of patients recovering from unstable angina pectoris
###end article-title 39
###begin article-title 40
###xml 71 79 <span type="species:ncbi:9606">children</span>
Allergen-induced cytokine secretion in atopic and non-atopic asthmatic children
###end article-title 40
###begin article-title 41
Complex assessment of differential cell count in bronchoalveolar lavage fluid as a distinction criterion between asthma and chronic obstructive pulmonary disease
###end article-title 41
###begin article-title 42
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial
###end article-title 42
###begin article-title 43
Airway exposure to bacterial superantigen (SEB) induces lymphocyte-dependent airway inflammation associated with increased airway responsiveness - a model for non-allergic asthma
###end article-title 43
###begin article-title 44
The association of sensitive systemic inflammation markers with bronchial asthma
###end article-title 44
###begin article-title 45
Association of bronchial hyperresponsiveness and lung function with C-reactive protein (CRP): a population based study
###end article-title 45
###begin article-title 46
Relevance of the selected cytokine release (TNF-alpha, IL-6, IFN-gamma, and IFN-alpha) to the exacerbation of bronchial asthma from airway mycotic infections. Predominant role of IFN-alpha?
###end article-title 46
###begin article-title 47
C-reactive protein is a risk indicator for atrial fibrillation after myocardial revascularization
###end article-title 47
###begin article-title 48
C-reactive protein, fibrin D-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies
###end article-title 48
###begin article-title 49
###xml 73 75 73 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink">NO</sub>
The influence of asthma and COPD exacerbation on exhaled nitric oxide (FENO)
###end article-title 49
###begin article-title 50
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Inflammatory response to acute inhalation of endotoxin in asthmatic patients
###end article-title 50
###begin article-title 51
Phenotypes of asthma revisited upon the presence of atopy
###end article-title 51
###begin article-title 52
###xml 112 120 <span type="species:ncbi:9606">patients</span>
Exhaled nitric oxide as a simple assessment of airway hyperresponsiveness in bronchial asthma and chronic cough patients
###end article-title 52
###begin article-title 53
C reactive protein levels are increased in non-allergic but not in allergic asthma: a multicentre epidemiological study
###end article-title 53
###begin article-title 54
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Relationship between exhaled carbon monoxide and airway hyperresponsiveness in asthmatic patients
###end article-title 54
###begin article-title 55
Standardized challenge testing with pharmacological physical and sensitizing stimuli in adults. Report working party standardization of lung function tests. European Community for Steal and Coal. Official statement of the European Respiratory Society
###end article-title 55
###begin article-title 56
C-reactive protein (CRP) and autoimmune disease: facts and conjectures
###end article-title 56
###begin article-title 57
###xml 56 71 <span type="species:ncbi:10090">transgenic mice</span>
###xml 83 88 <span type="species:ncbi:9606">human</span>
Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein
###end article-title 57
###begin article-title 58
###xml 145 153 <span type="species:ncbi:9606">patients</span>
Increased expression of the chemoattractant cytokines eotaxin, monocyte chemotactic protein-4, and interleukin-16 in induced sputum in asthmatic patients
###end article-title 58
###begin article-title 59
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Autologous serum skin test reactivity in patients with non-allergic asthma
###end article-title 59
###begin article-title 60
Bronchial inflammation and the common cold: a comparison of atopic and non-atopic individuals
###end article-title 60
###begin article-title 61
Association of CARD15 polymorphisms with atopy-related traits in a population-based cohort of Caucasian adults
###end article-title 61
###begin article-title 62
Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure
###end article-title 62
###begin article-title 63
###xml 111 114 <span type="species:ncbi:9606">men</span>
Bronchial responsiveness to methacholine is associated with increased common carotid intima-media thickness in men
###end article-title 63

